- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Citi agrees to acquire Kard Financial for commerce rewards | 2 | The Paypers | ||
| 14.08. | Citi to acquire US rewards tech company Kard Financial | 4 | FinTech Futures | ||
| 14.08. | Citi To Acquire Kard To Supercharge Personalized Rewards And Commerce Media | 3 | pulse2.com | ||
| 14.08. | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | 615 | AFX News | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| 13.08. | Citi to acquire commerce rewards platform Kard Financial | 4 | Investing.com | ||
| 13.08. | Citigroup übernimmt Commerce-Prämienplattform Kard Financial | 3 | Investing.com Deutsch | ||
| 11.08. | Kardigan, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| KARDIGAN Aktie jetzt für 0€ handeln | |||||
| 11.08. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 13.07. | TD Cowen initiates Kardigan stock with buy rating on cardiology pipeline | 2 | Investing.com | ||
| 13.07. | Kardigan: TD Cowen startet Coverage mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | JPMorgan initiates Kardigan stock with overweight on pipeline | 2 | Investing.com | ||
| 13.07. | Jefferies initiates Kardigan stock with buy rating on cardiology pipeline | 1 | Investing.com | ||
| 13.07. | Jefferies startet Kardigan mit Kaufempfehlung - Kardiologie-Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 13.07. | JPMorgan startet Kardigan-Aktie mit "Overweight" - Pipeline im Fokus | 2 | Investing.com Deutsch | ||
| 23.06. | How Kardigan spun deal leftovers into a $400M IPO | 1 | BioPharma Dive | ||
| 23.06. | Kardigan, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.06. | Kardigan erzielt 460 Millionen US-Dollar bei Börsengang an der NASDAQ | 2 | Investing.com Deutsch | ||
| 22.06. | Kardigan closes $460 million IPO on Nasdaq | 1 | Investing.com | ||
| 22.06. | Kardigan, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | 382 | Business Wire | SOUTH SAN FRANCISCO, Calif. & PRINCETON, N.J.--(BUSINESS WIRE)--Kardigan, Inc. (Nasdaq: KARD) ("Kardigan"), a clinical-stage precision therapeutics company developing medicines that target the root... ► Artikel lesen | |
| 18.06. | Kardigan's IPO Lands $400M for Drugs That Get to Root Causes of Heart Diseases | 1 | MedCity News |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INNOCAN PHARMA | 1,355 | -1,81 % | InnoCan Pharma: Die Strategie hinter dem Namenswechsel und was er bedeutet | ||
| JAGUAR HEALTH | 0,868 | 0,00 % | Jaguar Health, Inc.: Jaguar Health Reports Second Quarter 2026 Financials | Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure (IF) diseases; as announced, presentation at ESPGHAN 2026 described additional groundbreaking... ► Artikel lesen | |
| KALA BIO | 0,821 | -1,91 % | XFRA 27F: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILKALA BIO INC. O.N.... ► Artikel lesen | |
| IRONWOOD PHARMACEUTICALS | 3,660 | -0,54 % | Ironwood Pharmaceuticals, Inc. Profit Advances In Q2 | ||
| GALECTIN THERAPEUTICS | 3,100 | 0,00 % | Galectin Therapeutics Inc.: Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update | NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,190 | -0,45 % | Grace Therapeutics, Inc.: Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update | PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,380 | 0,00 % | Kazia Therapeutics Limited: Kazia Therapeutics Appoints James Levine as Chief Financial Officer | SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,660 | 0,00 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation | Encinitas, California--(Newsfile Corp. - August 19, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") today announced that it has licensed the development and commercialization rights... ► Artikel lesen | |
| INMED PHARMACEUTICALS | 1,300 | -0,76 % | Morning Market Movers: InMed Pharmaceuticals, INLIF Limited, China SXT Pharmaceuticals, Advanced Biomed See Big Swings | BEIJING (dpa-AFX) - At 8:30 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| MINDWALK | 1,190 | 0,00 % | MindWalk Holdings Corp. Reports Fiscal 2026 Results: Revenue Up 46% as the Company Completes Its Pivot to Bio-Native AI Infrastructure | Full-year revenue rose 46% to $15.6 million with gross margin expanding to 59%; net loss narrowed by more than half as MindWalk sharpened its focus on the BioIntelligence infrastructure powering... ► Artikel lesen | |
| LIPOCINE | 2,090 | 0,00 % | Lipocine Inc.: Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 | SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics... ► Artikel lesen | |
| HERON THERAPEUTICS | 0,260 | -4,05 % | Heron Therapeutics, Inc.: U.S. District Court Issues Decision Regarding CINVANTI Patents | CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the U.S. District Court... ► Artikel lesen | |
| INVENTIVA | 3,980 | 0,00 % | INVENTIVA: Inventiva Announces Preliminary Financial Results for the First Half of 2026 | Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026
Daix (France), New York City (New York, United States), July 30, 2026 - Inventiva (Euronext... ► Artikel lesen | |
| MEDICINOVA | 1,390 | 0,00 % | MediciNova passt Vorstandsverträge für CEO und CMO an | ||
| MILESTONE PHARMACEUTICALS | 1,050 | -0,47 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administered Treatment of Atrial Fibrillation with Rapid Ventricular Rate (AFib-RVR) | ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysmal Supraventricular Tachycardia (PSVT) Research Builds on Phase 2 Findings that Etripamil 70 mg Dose... ► Artikel lesen |
KARDIGAN INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -0,24 % bei einem Aktienkurs von 20,970 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KARDIGAN INC finden Sie auf Wallstreet Online.